Selinexor monotherapy (cytoreduction in BCR::ABL1-negative MPN)

Current understanding

A Phase II single-arm trial (trial-early evidence) is evaluating selinexor monotherapy as a cytoreductive agent across Philadelphia chromosome-negative MPNs — polycythemia vera, essential thrombocythemia, and primary myelofibrosis — over a 6-month treatment window. This represents the first prospective clinical evaluation of XPO1 nuclear export inhibition as standalone cytoreduction in MPNs, extending the selinexor program beyond MF-specific JAKi-combination and JAKi-naïve monotherapy contexts. Efficacy and safety endpoints are pending.

Evidence log

• 2026-06-04 — Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms: cross-connection with selinexor-monotherapy-mf: Parallel selinexor monotherapy programs: the cytoreduction trial spans PV/ET/PMF, while the MF-specific trial targets JAKi-naïve patients with moderate thrombocytopenia — together delineating the indication space for single-agent XPO1 inhibition in MPNs. (novelty: 4)

Open questions

Related